Changes in type 2 diabetes incidence and mortality associated with introduction of HbA1c as diagnostic option: A Danish 24-year population-based study

MLA

Jakob S. Knudsen, et al. “Changes in Type 2 Diabetes Incidence and Mortality Associated with Introduction of HbA1c as Diagnostic Option: A Danish 24-Year Population-Based Study.” The Lancet Regional Health. Europe, vol. 14, no. 100291-, Mar. 2022. EBSCOhost, https://doi.org/10.1016/j.lanepe.2021.100291.

APA

Jakob S. Knudsen, Signe S. Knudsen, Adam Hulman, Daniel R. Witte, Edward W. Gregg, Torsten Lauritzen, Lars Pedersen, Henrik T. Sørensen, & Reimar W. Thomsen. (2022). Changes in type 2 diabetes incidence and mortality associated with introduction of HbA1c as diagnostic option: A Danish 24-year population-based study. The Lancet Regional Health. Europe, 14(100291-). https://doi.org/10.1016/j.lanepe.2021.100291

Chicago

Jakob S. Knudsen, Signe S. Knudsen, Adam Hulman, Daniel R. Witte, Edward W. Gregg, Torsten Lauritzen, Lars Pedersen, Henrik T. Sørensen, and Reimar W. Thomsen. 2022. “Changes in Type 2 Diabetes Incidence and Mortality Associated with Introduction of HbA1c as Diagnostic Option: A Danish 24-Year Population-Based Study.” The Lancet Regional Health. Europe 14 (100291-). doi:10.1016/j.lanepe.2021.100291.